Scarica l'app Stockscreener
0.491
3.88%
-0.0198
Dopo l'orario di chiusura:
.48
-0.011
-2.24%
Precedente Chiudi:
$0.5108
Aprire:
$0.51
Volume 24 ore:
680.84K
Relative Volume:
0.12
Capitalizzazione di mercato:
$8.30M
Reddito:
-
Utile/perdita netta:
$-14.58M
Rapporto P/E:
-0.427
EPS:
-1.15
Flusso di cassa netto:
$-9.80M
1 W Prestazione:
-21.88%
1M Prestazione:
+26.35%
6M Prestazione:
-39.68%
1 anno Prestazione:
-77.06%
Intervallo 1D:
$0.487
$0.5342
Intervallo di 1 settimana:
$0.43
$0.63
Portata 52W:
$0.30
$3.325
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Nome
Acurx Pharmaceuticals Inc
Settore
Industria
Telefono
917-533-1469
Indirizzo
259 LIBERTY AVENUE, STATEN ISLAND
Confronta ACXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
0.491 | 8.30M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Yahoo Finance
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Investors Purchase Large Volume of Acurx Pharmaceuticals Call Options (NASDAQ:ACXP) - Defense World
Acurx Pharmaceuticals Raises Fresh $2.67M Capital: New Antibiotic Development Gets Major Funding Boost - Stock Titan
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ - Yahoo Finance
Acurx Pharmaceuticals Inc (ACXP) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Crude Oil Rises Sharply; Jabil Earnings Top Views - Benzinga
US Stocks Lower; Retail Sales Decline In May - Benzinga
Power Metallic (TSX.V: PNPN) Secures Largest Saudi License Amid June 2025 Gold Surge – Material Gains & More Stocks Inside - FinancialContent
Acurx Pharmaceuticals Soars as Breakthrough Antibiotic Data Hits the Headlines - RagingBull
Banco Santander S.A. ADR Inc. (SAN) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Why Is Acurx Pharmaceuticals Stock (ACXP) Up 250% Today? - TipRanks
Breakthrough: New Antibiotic Achieves 94% Cure Rate Against C. Difficile, Outperforms Standard Treatment - Stock Titan
(PDF) A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens - researchgate.net
Mirum Pharmaceuticals Expands Team with 10 New Hires, Grants $5.7M Stock Options Package - Stock Titan
TJX Maintains Strong Dividend Program: Top Retail Chain Announces $0.425 Per Share Payout - Stock Titan
New to The Street's Documentary Specials Break Records: IMG Academy Surpasses 126,000 Views in Just 12 Days - Akron Beacon Journal
Acurx announces presentation of results for DNA pol IIIC inhibitors - TipRanks
Acurx Pharmaceuticals Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA pol IIIC Inhibitors - marketscreener.com
Acurx (ACXP) Advances Antibiotic Candidate for C. difficile Treatment | ACXP Stock News - GuruFocus
Warner Bros. Discovery to split into two companies, dividing cable and streaming services - WFMZ.com
Breakthrough: New Antibiotic Class Shows Promise Against Drug-Resistant C. DifficilePhase 3 Ready - Stock Titan
Clostridium Difficile Infections Pipeline 2025: MOA and ROA - openPR.com
Popular Inc Delivers Double Income Stream: New Preferred Stock Dividend Plus Trust Securities Distribution - Stock Titan
Exclusive: Aptar Leadership Team Set for Strategic Updates at Major Investment Conferences - Stock Titan
Medical Properties Trust Dividend Alert: $0.08 Per Share Payable July 17Key Dates Inside - Stock Titan
Exicure Faces Nasdaq Delisting Risk: 60 Days to Submit Compliance Plan for Late Q1 Filing - Stock Titan
Ardent Health Partners Streamlines Brand Identity: What the New Corporate Name Means for Investors - Stock Titan
Chikungunya wins boost Valneva; overall infectious disease stocks fall - BioWorld MedTech
ACXP Stock: Selling Stockholder to Offload Shares with No Procee - GuruFocus
ACXP Stock: Selling Stockholder to Offload Shares with No Proceeds to Company | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals Inc Files For Resale Of Up To 10.9 Million Shares Of Common Stock By The Selling StockholderSEC Filing - marketscreener.com
Q2 Earnings Forecast for ACXP Issued By HC Wainwright - Defense World
HC Wainwright Reaffirms “Buy” Rating for Acurx Pharmaceuticals (NASDAQ:ACXP) - Defense World
Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment - MSN
Acurx Pharmaceuticals’ Earnings Call: Progress Amidst Funding Challenges - TipRanks
ACXP: Acurx Pharmaceuticals Receives 'Buy' Rating from HC Wainwr - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock - Investing.com Australia
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 T - GuruFocus
H.C. Wainwright sets $8 target for Acurx Pharmaceuticals stock By Investing.com - Investing.com India
H.C. Wainwright Initiates Buy Coverage on Acurx (ACXP) with $8 Target | ACXP Stock News - GuruFocus
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call Transcript - Insider Monkey
Acurx Pharmaceuticals Reports Improved Q1 2025 Results - TipRanks
Earnings call transcript: Acurx Pharmaceuticals beats Q1 2025 EPS forecast By Investing.com - Investing.com India
Acurx Pharmaceuticals Q1 Net Income USD -2.1 Million - marketscreener.com
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update - Stock Titan
Acurx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Tesla Stock Is Climbing Monday: What's Going On?Tesla (NASDAQ:TSLA) - Benzinga
Acurx Pharmaceuticals (ACXP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement - TipRanks
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y - Yahoo Finance
Acurx Pharmaceuticals Inc Azioni (ACXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acurx Pharmaceuticals Inc Azioni (ACXP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):